To evaluate the efficacy and tolerability of telmisartan, given once a day to patients with mild to moderate hypertension, as well as to assess the 24-hour blood pressure profile with ABPM
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
134
Changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP)
Blood pressure values were obtained 24 hours after the last dose (through values) at the office
Time frame: Baseline, up to 12 weeks after start of treatment
Assessment of treatment response for SBP/DBP (in %)
Response categories: * SBP \< 140 mm Hg or * DBP \< 90 mm Hg or * BP reduction ≥ 10 mm Hg
Time frame: Baseline, up to 12 weeks after start of treatment
Changes from baseline in blood pressure values
Analysis performed for the ambulatory blood pressure monitoring (ABPM) - subgroup
Time frame: Baseline, up to 12 weeks after start of treatment
Number of patients with adverse events
Time frame: Up to 16 weeks
Number of patients with clinically significant changes in laboratory values
Time frame: Up to 16 weeks
Number of patients with clinically significant changes in ECG
Time frame: Up to 16 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.